Are statins proven to work for women or children

The short version: statins clearly prevent heart attacks and strokes in high-risk women, but the case for routine statins in healthy women is weak, and in children there is no proof of clinical benefit at all.

For women with existing heart disease, the evidence is real and specific to them. A JUPITER subgroup analysis found rosuvastatin cut the combined heart event endpoint in women by nearly half (HR 0.54), with women faring as well as men on the primary endpoint [2]. In PROVE IT, women with acute coronary syndrome on intensive statins had a 25% relative drop in the composite endpoint [3]. In SPARCL, women had a hazard ratio of 0.84 for stroke and 0.67 for any heart disease event on atorvastatin, with no significant sex interaction [4]. These are secondary prevention, meaning sick women, not healthy ones.

For primary prevention, the picture is weaker. A pooled analysis of three trials found statins cut cardiovascular events in women by about a third (RR 0.63), but this was driven mostly by one trial and the mortality benefit was not significant (RR 0.78, p=0.21) [2]. In MEGA, pravastatin cut all-cause deaths in women by 41%, but not heart disease events themselves [5]. And in ASCOT-LLA, atorvastatin did not reduce the primary endpoint in women at all (HR 1.1), while it clearly helped men (HR 0.59) [5]. Against that, rosuvastatin raised new diabetes in women (HR 1.49 live births vs 1.14) in JUPITER, one case per 1000 women per year [1].

For children, the evidence is essentially all about lipid numbers, not outcomes. A Cochrane review found statins lower LDL in kids with familial hypercholesterolemia, but flagged the absence of long-term studies [6]. Simvastatin raised flow-mediated dilation in one small trial [7], and a 20-year follow-up found early statin use slowed artery wall thickening and cut later heart disease events [8]. But the largest pediatric trial (173 kids, up to 48 weeks) reported no serious adverse events and similar growth and puberty — over roughly a year [9]. The question the reader actually has — does treating a child with statins prevent a heart attack or death decades later — is answered only by that single observational follow-up [8], not by randomized outcome data. No trial has compared treated children to untreated children for hard clinical events.

My call: for women with established heart disease, statins are proven to reduce events, moderate confidence. For healthy women, the benefit is modest and the diabetes signal is real — a weak case. For children with familial hypercholesterolemia, LDL falls and short-term safety looks acceptable, but no randomized trial has shown clinical benefit, so the claim that treating kids prevents future heart attacks is unproven. Confidence in that: moderate.